Vicore: Additional IPF Data Reinforces Efficacy Signals - Redeye

Redeye is overall positive to the second interim analysis from Vicore’s phase II trial in IPF with drug candidate C21, that largely confirms the previous efficacy data in a somewhat larger sample. We reiterate our base case of SEK 78 and will participate in today’s call before we likely return with an additional take.

Länk till analysen i sin helhet: https://www.redeye.se/research/861361/vicore-additional-ipf-data-reinforces-efficacy-signals?utm_source=finwire&utm_medium=RSS